The table below shows Kymera Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$232.89M
-$194.50M
-$102.83M
-$153.09M
-$128.95M
$88.13M
Capital expenditure
$1.45M
$12.84M
$34.48M
$2.84M
$1.60M
$9.10M
Investing cash flow
-$521.06M
-$404.08M
$139.89M
$20.52M
-$99.83M
-$422.59M
Dividends paid
-
-
-
-
-
KYMR operating cash flow (10-K history)
Kymera Therapeutics, Inc. reported operating cash flow of -$232.89M for fiscal year 2025. That is down 19.7% from -$194.50M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from $17.91M (FY 2019) to -$232.89M. Figures come from the company's audited annual reports as filed with the SEC.
